Progression-Free Survival
CPS
In KEYNOTE-059, median PFS based on independent central review was 2 months in all patients and in the CPS ≥ 1 population (Fig. Kaplan–Meier estimates of progression-free survival in Japanese patients from In the CPS ≥ 1 population of KEYNOTE-061, median PFS (pembrolizumab vs. chemotherapy) was 2 versus 4 months (HR, 1.21; 95% CI, 0.69–2.13) (Fig. In the CPS ≥ 1 population of KEYNOTE-062, median PFS (pembrolizumab vs. chemotherapy) was 6 versus 7 months (HR, 1.03; 95% CI, 0.61–1.74) (Fig. 